The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).

Hui Kong Gan

Employment or Leadership Position - Ludwig Institute for Cancer Research

Lisa Fichtel

No relevant relationships to disclose

Andrew B. Lassman

Consultant or Advisory Role - Abbott Laboratories; Able Associates; Agenus; Amgen; Defined Health; Easton Associates; GlaxoSmithKline; Kyowa Hakko Kirin; Merck Sharp & Dohme; Novartis; RadMD; Roche/Genentech; Scientific Advisors; Sigma-Tau; Stemline; Synapse; Venture Inflections

Honoraria - American Physician Inst; Merck Sharp & Dohme; OmniPrex America; Robert Michael Educational Inst

Research Funding - AbbVie; Agenus; Amgen; Boehringer Ingelheim; Celldex; Genentech; MedImmune; Northwest Biotherapeutics; Novartis; NPM Pharma; Pfizer; Plexxikon

Ryan Merrell

No relevant relationships to disclose

Martin J. Van Den Bent

Consultant or Advisory Role - AbbVie; Actelion; Amgen; Celldex; MSD; Roche

Research Funding - AbbVie; Roche

Priya Kumthekar

No relevant relationships to disclose

Andrew Mark Scott

Employment or Leadership Position - Ludwig Institute for Cancer Research

Consultant or Advisory Role - Life Science Pharmaceuticals (U)

Stock Ownership - Life Science Pharmaceuticals

Michelle Pedersen